Loading...
XSTO
BIOG B
Market cap1.02bUSD
Apr 17, Last price  
100.70SEK
1D
-1.27%
1Q
-11.59%
Jan 2017
67.83%
Name

Biogaia AB

Chart & Performance

D1W1MN
No data to show
P/E
27.93
P/S
6.90
EPS
3.61
Div Yield, %
4.97%
Shrs. gr., 5y
3.14%
Rev. gr., 5y
13.11%
Revenues
1.42b
+9.73%
59,606,00086,792,000106,580,000145,190,000203,461,000236,033,000314,992,000645,252,000315,875,000481,802,000483,241,000534,696,000615,003,000741,870,000768,348,000747,077,000785,111,0001,103,958,0001,296,506,0001,422,718,000
Net income
351m
-3.82%
-19,825,0002,720,00019,659,00036,121,00036,045,00047,168,00076,369,000326,970,00061,722,000147,406,000121,408,000227,568,000180,564,000214,890,000187,347,000179,730,000196,273,000373,773,000365,352,000351,388,000
CFO
373m
-12.38%
-9,969,000-831,0005,088,00019,204,00053,290,00068,965,00072,792,000335,557,00078,441,000124,383,000117,501,000147,929,000222,615,000183,120,000147,855,000221,256,000221,875,000318,943,000425,965,000373,218,000
Dividend
May 08, 20256.9 SEK/sh
Earnings
May 05, 2025

Profile

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylori–the gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
URL
https://sv.biogaia.com/
IPO date
Jan 01, 1998
Employees
215
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,422,718
9.73%
1,296,506
17.44%
1,103,958
40.61%
Cost of revenue
1,013,357
855,597
769,449
Unusual Expense (Income)
NOPBT
409,361
440,909
334,509
NOPBT Margin
28.77%
34.01%
30.30%
Operating Taxes
96,431
103,482
73,840
Tax Rate
23.56%
23.47%
22.07%
NOPAT
312,930
337,427
260,669
Net income
351,388
-3.82%
365,352
-2.25%
373,773
90.44%
Dividends
(696,778)
(292,849)
(301,331)
Dividend yield
Proceeds from repurchase of equity
20,815
(417)
(428)
BB yield
Debt
Debt current
8,800
20,088
Long-term debt
35,156
20,926
Deferred revenue
(4,913)
Other long-term liabilities
98,425
91,932
64,005
Net debt
(1,223,984)
(1,528,249)
(1,473,145)
Cash flow
Cash from operating activities
373,218
425,965
318,943
CAPEX
(13,756)
(48,568)
(17,916)
Cash from investing activities
(14,073)
(50,935)
(18,141)
Cash from financing activities
(689,718)
(308,421)
(313,588)
FCF
316,976
269,702
243,209
Balance
Cash
1,223,984
1,544,192
1,488,366
Long term investments
28,013
25,793
Excess cash
1,152,848
1,507,380
1,458,961
Stockholders' equity
2
876,967
818,624
Invested Capital
1,822,357
1,254,109
1,212,150
ROIC
20.34%
27.36%
21.04%
ROCE
22.40%
20.54%
16.37%
EV
Common stock shares outstanding
101,162
100,982
100,982
Price
Market cap
EV
EBITDA
486,056
466,190
358,399
EV/EBITDA
Interest
14,924
809
5,386
Interest/NOPBT
3.65%
0.18%
1.61%